Tilray Inc. (TLRY) shares continued their upward trajectory, surging 5.04% in pre-market trading on Tuesday. This follows a remarkable 20.87% rally during Monday's regular trading session, extending the stock's gains for the third consecutive day. The cannabis company's stock has been outperforming the broader market amid renewed optimism in the sector.

The significant rally is primarily driven by two key factors. Firstly, Jefferies analyst Kaumil Gajrawala maintained a Buy rating on Tilray while raising the price target from $1.50 to $2.00, signaling increased confidence in the company's prospects. This upgrade represents a potential upside of 43.88% from current levels and has bolstered investor sentiment.

Secondly, growing optimism surrounding potential U.S. cannabis reform has buoyed the entire industry. Reports suggest that marijuana could be rescheduled to Schedule III of the Controlled Substances Act before year-end, a move that would significantly benefit cannabis companies like Tilray. This rescheduling would allow them to take advantage of tax write-offs and credits, potentially improving their financial outlook. Additionally, there's increasing speculation about the passage of the SAFER Banking Act, albeit likely in the 2025-2026 session. These potential regulatory changes have sparked renewed interest in cannabis stocks, with Tilray leading the charge. The stock's trading volume has surged to more than double its 50-day average, underscoring the heightened investor activity surrounding these developments.